CD8A and neoplasm: In the absence of any therapeutic effect, doxorubicin failed indeed to promote the infiltration of B16 tumors by CD3+CD4+ and CD3+CD8+ T cells, irrespective of autophagic-proficiency, although it did promote some activation in the pre-existing tumor infiltrate (as per intratumoral levels of CD3+CD4+CD44+ and CD3+CD8+CD44+ cells [55].